Aktie A0M3RD HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Aktien

A0M3RD

CNE000000BF3

600671

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 28.05.2024 		% 5 Tage % 1. Jan.
8,12 CNY -4,47 % Intraday Chart für Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd -4,58 % -30,36 %
24.05. Tianmushan Pharmaceutical Enterprise will Produktionslinie für 100 Millionen Yuan umbauen MT
26.04. Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd meldet Ergebnis für das erste Quartal zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Tianmushan Pharmaceutical Enterprise to Revamp Production Line for 100 Million Yuan
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved.
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise.
TianMuShan Pharma Elects Chairman
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
TianMuShan Pharmaceutical CFO Steps Down
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million.
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd.
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0M3RD Aktie
  4. Nachrichten Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
  5. Andere Sprachen